Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 7/20 | 0.44 |
| ▸ | CNR1 | P21554 | 4/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10030732 | 0.91 | EPHX2 (0.48) | HPGDCNR2TAAR1HDAC1HDAC2 | |
| SCHEMBL19617998 | 0.91 | HPGD (0.56) | HPGDSMN1; SMN2CNR2CNR1TAAR1 | |
| SCHEMBL10030729 | 0.91 | HPGD (0.56) | HPGDSMN1; SMN2CNR2CNR1TAAR1 | |
| SCHEMBL10030733 | 0.90 | HPGD (0.47) | HPGDCNR2CNR1MEN1KMT2A | |
| SCHEMBL4570246 | 0.90 | DGKA (0.47) | HPGDCNR2CNR1EPHX2 | |
| SCHEMBL12451260 | 0.90 | DGKA (0.47) | HPGDCNR2CNR1EPHX2 | |
| SCHEMBL14370086 | 0.88 | DGKA (0.45) | HPGDCNR2CNR1EPHX2 | |
| SCHEMBL10033435 | 0.88 | DGKA (0.49) | HPGDMAPTEPHX2 | |
| SCHEMBL4570248 | 0.88 | MAPT (0.43) | SMN1; SMN2CNR2CNR1MAPT | |
| SCHEMBL838287 | 0.88 | MAPT (0.43) | SMN1; SMN2CNR2CNR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012527-B2 | Curable compositions for three-dimensional printing | XEROX CORPORATION (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012527-B2 | Curable compositions for three-dimensional printing | XEROX CORPORATION (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140053754-A1 | CURABLE COMPOSITIONS FOR THREE-DIMENSIONAL PRINTING | XEROX CORPORATION (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140053754-A1 | CURABLE COMPOSITIONS FOR THREE-DIMENSIONAL PRINTING | XEROX CORPORATION (US) | 2014-02-27 | — | — | US | disclosed |
| US-8581000-B2 | Process for preparing amide gellant compounds with aromatic end groups | XEROX CORPORATION (US) | 2013-11-12 | — | — | US | disclosed |
| US-8507584-B2 | Phase change inks containing amide gellant compounds with aromatic end groups | XEROX CORPORATION (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507584-B2 | Phase change inks containing amide gellant compounds with aromatic end groups | XEROX CORPORATION (US) | 2013-08-13 | — | — | US | disclosed |
| US-20120309924-A1 | Process for Preparing Amide Gellant Compounds with Aromatic End Groups | XEROX CORPORATION (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120282448-A1 | METHODS FOR FABRICATING THREE-DIMENSIONAL OBJECTS | XEROX CORPORATION (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120282448-A1 | METHODS FOR FABRICATING THREE-DIMENSIONAL OBJECTS | XEROX CORPORATION (US) | 2012-11-08 | — | — | US | disclosed |
| US-8084637-B2 | Amide gellant compounds with aromatic end groups | XEROX CORPORATION (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084637-B2 | Amide gellant compounds with aromatic end groups | XEROX CORPORATION (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110262643-A1 | INK COMPOSITIONS AND METHODS | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263890-A1 | Amide Gellant Compounds With Aromatic End Groups | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263890-A1 | Amide Gellant Compounds With Aromatic End Groups | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263769-A1 | Phase Change Inks Containing Amide Gellant Compounds With Aromatic End Groups | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262711-A1 | CURABLE COMPOSITIONS FOR THREE-DIMENSIONAL PRINTING | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262711-A1 | CURABLE COMPOSITIONS FOR THREE-DIMENSIONAL PRINTING | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262643-A1 | INK COMPOSITIONS AND METHODS | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263769-A1 | Phase Change Inks Containing Amide Gellant Compounds With Aromatic End Groups | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263890-A1 | Amide Gellant Compounds With Aromatic End Groups | NAT1, AGPAT2, CCNT1 | THRB 3422/4885HPGD 3248/4885SMN1; SMN2 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.